non-small cell lung cancer

Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Flag link:
Novartis’s canakinumab cancer test approaches
Novartis’s canakinumab cancer test approaches
EP Vantage
Novartis
Regeneron
canakinumab
cancer
non-small cell lung cancer
Flag link:
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
BioSpace
Merck
Keytruda
Bristol-Myers Squibb
Yervoy
non-small cell lung cancer
Flag link:
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
Endpoints
JNJ
amivantamab
non-small cell lung cancer
Flag link:
Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag
Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag
Endpoints
Takeda
lung cancer
mobocertinib
non-small cell lung cancer
Flag link:
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq
Pharmaceutical Business Review
Roche
FDA
tiragolumab
Tecentriq
non-small cell lung cancer
breakthrough therapies
Flag link:
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
JNJ
amivantamab
Flag link:
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer
Flag link:
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Flag link:
Jounce shares crash after it abandons immunotherapy combination trial
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Flag link:
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Flag link:
Triple meeting – the point of turning to TPX-0022
Triple meeting – the point of turning to TPX-0022
EP Vantage
Turning Point Therapeutics
repotrectinib
TPX-0022
non-small cell lung cancer
Flag link:
Merck touts new data for Keytruda combos in NSCLC at North American conference
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Flag link:
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
BioSpace
Bristol-Myers Squibb
clinical trials
non-small cell lung cancer
Opdivo
Flag link:
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Fierce Biotech
Amgen
clinical trials
non-small cell lung cancer
KRAS
sotorasib
Flag link:
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
Flag link:
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Flag link:
Amgen publishes, presents data on therapy with ‘undruggable’ target
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
Flag link:
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
Flag link:
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Flag link:

Pages